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Fungal keratitis is a common disease in certain parts of the world and affects several
species, including equids, camelids, and homo sapiens, leading to blindness or loss of
the eye if the infection is not adequately controlled. Reports of clinical use of antifungals
caspofungin and terbinafine are limited across both veterinary and human medical
literature. The alpaca presented in this case demonstrates that deep keratomycosis
can be caused by Scopulariopsis brevicaulis and Fusarium verticillioides, two previously
unreported fungi to cause keratomycosis in camelids. This report demonstrates
successful management with a combination of surgery and topical ophthalmic treatment
with caspofungin 0.5% solution and terbinafine 1% dermatologic cream, after initially
failing treatment with topical voriconazole 1% solution. Combination therapy appears
more effective than monotherapy with some fungal organisms, and synergy between
antifungal agents is thought to play a role in the success of combination therapy. Surgery
to remove the bulk of the fungal infection is especially helpful in cases that fail initial
medical therapy.
Keywords: camelid ophthalmology, Scopulariopsis brevicaulis, Fusarium verticillioides, corneal abscess, corneal
crosslinking, keratomalacia, fungal keratitis
BACKGROUND
New world camelids, especially alpacas, are increasingly popular as companion animals or for fiber
production in North America (1). Like horses, alpacas have prominent eyes prone to traumatic
corneal disease and risk secondary microbial infection (1, 2). Fungi are normal inhabitants of the
ocular surface microflora in healthy New World camelids (56% positive growth). One study from
the Northeastern United States described a 6.5% prevalence of fungal keratitis (keratomycosis) in
camelids, similar to equine data (5.7–8.6% prevalence) (1, 3).
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Keratomycosis occurs in humans also; however, the
prevalence of fungal keratitis varies widely, due to climate, age,
gender, socioeconomics, and urbanization (4–6). Keratomycosis
can be challenging to manage and may result in a loss of vision
or the eye if not treated appropriately. This report describes the
successful management of an alpaca with a full-thickness corneal
abscess associated with two fungi, Scopulariopsis brevicaulis and
Fusarium verticillioides.
CASE PRESENTATION
An 11-year-old female alpaca was presented to the Lloyd
Veterinary Medical Center at the Iowa State University (LVMC-
ISU) for evaluation of suspected corneal infection and recent
weight loss. Ten days prior to referral, the owner noted
that the alpaca had acute epiphora and blepharospasm of
the right eye (OD). Topical neomycin-polymyxin B-bacitracin
(NPB) ophthalmic ointment was initiated twice daily by the
family veterinarian (rDVM) for a corneal ulcer OD diagnosed
via fluorescein staining. Trauma was not observed but was
the suspected cause given the species and group housing
environment. Acute worsening of the ulcer occurred within 1
week and treatment was switched to topical ofloxacin 0.3% and
atropine 1% (each twice daily) and oral meloxicam (60mg once
daily) until referral. No other diagnostics or treatments were
performed by the rDVM.
On presentation (day 1), physical examination revealed
a slightly low body condition score of 3/9; however, vitals,
capillary refill time, mucus membrane color, FAMACHA score,
cardiothoracic auscultation, and first compartment contractions
were all within normal limits. Fecal parasitology assessment was
previously performed by the rDVM. Ophthalmic examination
was performed with slit lamp biomicroscopy (SL-17, Kowa,
Tokyo, Japan) and indirect ophthalmoscopy (Keeler Vantage,
Keeler instruments Inc., Broomall, PA, USA). The left eye (OS)
was normal. OD had a positive but inconsistent menace response,
positive palpebral and dazzle reflexes, and reduced direct and
consensual (right to left) pupillary light reflexes. Moderate
blepharospasm and mucopurulent discharge were present. The
conjunctiva was moderately hyperemic, the cornea had a 5 ×
6mm yellow creamy paraxial stromal abscess with fluffy borders,
a few surrounding pinpoint satellite lesions in the adjacent
stroma, severe corneal edema with secondary bullae, dense
stromal vascularization, and several ≤1mm regions of positive
fluorescein uptake overlying the abscess (Figure 1A). Aqueous
flare (grade 2/4) was noted; although, deeper structures (lens,
vitreous, fundus) were not visualized due to miosis and severity
of anterior segment disease.
The main etiologic differentials for the corneal abscess were
bacteria or fungi. Corneal cytology and culture were obtained
from an area denuded of epithelium. Cytology, evaluated
by a board-certified clinical pathologist, showed neutrophilic
inflammation without any evidence of microorganisms. Surgical
management was discussed but initially declined. The alpaca
was hospitalized and subpalpebral lavage was placed in the
lower conjunctival fornix. Intensivemedical therapy was initiated
while awaiting bacterial and fungal culture results: 0.2mL
voriconazole 1% (compounded into sterile water) q4h, 0.2mL
ofloxacin 0.3% ophthalmic solution (o.s.) q2h, 0.2mL cefazolin
5.5% (compounded into artificial tears) q2h, 0.2mL heterologous
canine plasma q2h, 0.2ml atropine 1% o.s. q12h, and 0.2mL
sodium chloride 5% o.s. q6h OD. Meloxicam (60mg PO q72h)
was initiated once the alpaca began eating well. On day 2, a
satellite lesion adjacent to the stromal abscess had substantially
increased in size by roughly 3mm, the corneal bullae had
worsened, and the pupil remained miotic (Figure 1B); therefore,
the frequency of voriconazole and atropine was increased to
q2h and q8h, respectively. The subpalpebral lavage line was
prematurely removed by the patient 48 h after placement, thus
medications were continued by squirting solutions onto the right
eye with a tuberculin syringe and 25-gauge needle hub.
On day 3, despite aggressive medical management, the
two stromal abscesses had coalesced, the corneal bullae had
worsened, the overlying cornea appeared malacic, and the
epithelial defect had increased in size to nearly cover the entire
abscess (Figure 1C). On day 4, corneal cross linking (CXL) was
performed while the patient was standing with no sedation,
using the accelerated protocol: topical instillation of 0.1%
isotonic riboflavin without dextran (Peschke R© M, Huenenberg,
Switzerland) at one drop every 2min for 20min, followed by UV-
A irradiation (365 nm; Nitecore CUC Chameleon LED flashlight
with UV, Austin, TX, USA) at approximately 45 mW/cm2 for
2.5min; of note, the light intensity was verified with a UVA/B
light meter (General Tools & Instruments, Secaucus, NJ, USA)
prior to the procedure. A subconjunctival injection of 0.5mL
voriconazole 1% was performed after CXL. The procedure
rapidly halted the keratomalacia, but the corneal abscess size and
appearance remained unchanged.
On day 5, bacterial culture was reported negative and
the corneal malacia was stable, therefore the frequency of
cefazolin, ofloxacin, and plasma was reduced to q4h. However,
the corneal stromal abscess continued to increase in size
another 2mm by day 7 (Figure 1D). On day 9, fungal
culture revealed Scopulariopsis brevicaulis growth, an organism
reportedly resistant to several antifungal agents (7–9). With
positive growth of a fungus known to be more challenging
to treat medically, the expected continued intensity of topical
medications, and desire to preserve vision, surgical keratoplasty
was now elected (day 10).
A pre-operative packed cell volume (30%) and total solids (6.0
g/dL) were within normal limits. The alpaca was administered
fentanyl (2.5 mg/kg, IV) and midazolam (0.25 mg/kg, IV)
for pre-operative analgesia and sedation then induced with
propofol (3 mg/kg, IV) and ketamine (2.5 mg/kg, IV) and
maintained with isoflurane in oxygen following orotracheal
intubation. An intra-operative blood gas was within normal
limits. The alpaca was positioned in left lateral recumbency.
The periocular area was aseptically clipped, prepared, and
draped routinely. A large Castroviejo eyelid speculum was
placed followed by a stay suture in the ventromedial sclera
at the limbus with 5-0 silk to gently manipulate the globe
to the desired position, negating the need for intraoperative
neuro-muscular blockade.
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FIGURE 1 | Photographs of the progression of a refractory fungal stromal abscess of the right eye in an 11-year-old female alpaca on day 1 (A), day 2 (B), day 3 (C),
and day 7 (D). (A)–Day 1, on presentation, there is approximately a 5mm paraxial stromal abscess with a yellow creamy appearance and fluffy borders, pinpoint
satellite lesions in the adjacent stroma (unable to appreciate in photo), marked geographical corneal edema, and dense stromal corneal vascularization. Photo
obtained prior to application of fluorescein stain. (B)–By day 2, a satellite lesion adjacent to the stromal abscess had substantially increased in size by roughly 3mm
and the multiple small corneal bullae had worsened/coalesced to become a large corneal bulla overlying the medial aspect of the lesion with fluorescein stain uptake.
(C)–By day 3, despite aggressive medical management the two stromal abscesses had coalesced, the corneal bullae had progressed, and the overlying cornea
appeared moderately malacic. Photo obtained prior to use of fluorescein stain; after application it was noted the ulcer had increased in size to cover the whole lesion.
Corneal cross linking with the accelerated protocol was performed the following day. (D)–On day 7, the stromal abscess had continued to increase by ∼2mm with
improvement in corneal bullae, malacia, and progression of stromal vascularization. Fluorescein staining is evident overlying a portion of the abscess.
The corneal abscess measured 10 × 8mm in size. A #6900
beaver blade was used to incise 0.5mm away from the diseased
cornea to a depth of ∼50% then perform lamellar dissection at
this depth. A round 3mm full thickness abscess was unveiled
after the lamellar keratectomy was achieved. Graft materials
were prepared including an 11 × 9mm island conjunctival graft
harvested from the anterior surface of the third eyelid using a
chalazion clamp and Westcott tenotomy scissors and a 3mm 4
ply porcine small intestinal submucosa graft (BioSIS bioscaffold
multilayer, Vetrix Plus, Cumming, GA, USA) obtained with a
biopsy punch. Interestingly, the third eyelid proved to have
minimal to no connective tissue or cartilage between the
anterior and posterior conjunctiva, thus special care was needed
during blunt dissection of the conjunctival graft. A penetrating
keratoplasty (PK) was performed as previously described in
horses (10). In short the following steps were performed: (1)
PK was initiated with a 3mm biopsy punch down to Descemet’s
membrane, (2) Vetrix Plus was preplaced into the wall of the
corneal defect at six o’clock and two additional sutures were
preplaced into the Vetrix Plus at three and nine o’clock, (3) a
21-gauge needle was pierced through Descemet’s membrane, (4)
viscoelastic (Hyvisc, Boehringer Ingelheim, St. Joseph,MO,USA)
re-inflated the anterior chamber, (5) corneal section scissors
excised the remainder of the corneal abscess, (6) followed by
two additional sutures to secure the Vetrix to the PK site.
The harvested island conjunctival graft was secured into the
lamellar keratectomy site. All corneal and graft sutures were
performed with 8-0 polyglactin 910 suture (Figure 2A). A lateral
temporary tarsorrhaphy was placed with 5-0 silk suture in an
interrupted horizontal mattress pattern. The deep keratectomy
sample was submitted for aerobic bacterial and fungal cultures,
but histopathology was declined due to financial restraints.
The alpaca’s medications were adjusted post-operatively to
include: 0.1mL ofloxacin 0.3% o.s. q4h, 0.1mL atropine 1% o.s.
q8h, 0.1mL 5% sodium chloride o.s. q8h, 0.1mL caspofungin
0.5% (compounded into 0.9% sodium chloride) q6h, and ¼ inch
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FIGURE 2 | Photographs of the right eye of an 11-year-old female alpaca post-operatively after penetrating keratoplasty for a fungal stromal abscess immediately
after surgery (A) and 4 weeks after surgery (B). (A)–A 3mm 4 ply porcine small intestinal submucosa graft (Vetrix Plus) was placed within the penetrating keratoplasty
site with an 11 × 9mm island conjunctival graft overlying the lamellar keratectomy site of 50% stromal depth, sutured in place with 8-0 polyglactin 910 suture. (B)–The
eye was visual and comfortable 4 weeks after surgery with a healthy island conjunctival graft, sutures intact but dissolving, and a dilated pupil.
strip of terbinafine 1% dermal cream (Lamisil, GlaxoSmithKline,
Brentford, UK) OD, as well as meloxicam 60mg PO q72h. In
addition, ceftiofur crystalline-free acid (6.6 mg/kg, SC once)
was added for a fever (102.9 ◦F) of <12 h duration, and
pantoprazole (1 mg/kg, IV once daily for 2 days) for suspected
third compartment ulceration. Recovery following surgery was
otherwise unremarkable. The alpaca was discharged into the care
of the owner on day 14 with the following recommendations:
0.1mL caspofungin 0.5%, 0.1mL ofloxacin 0.3% o.s., and ¼ inch
strip terbinafine 1% dermal cream each q6h, as well as 0.1mL
atropine 1% o.s. q12h OD for 2 weeks then once daily until
recheck. The maximum frequency of medications the owners
were able to manage at home was q6h. The patient was continued
on meloxicam 60mg PO q72h for 2 weeks.
Culture results were available on day 20 and reported growth
of Fusarium verticillioides but no bacterial growth. Due to the
higher cost of the caspofungin solution, the owners did not refill
this medication and ran out within ∼3 weeks (day 32); all other
medications were continued as recommended. The alpaca was
rechecked 4 weeks after surgery (day 37) and was visual (noted
by a positive menace response and behavior observation) and
comfortable OD. Intraocular pressures were 16 mmHg OD and
13 mmHg OS as obtained with a rebound tonometer (TonoVet,
ICare Finland Oy, Helsinki, Finland) in the equine setting. The
dense stromal vascularization had regressed, the island graft was
pink and healthy, sutures remained intact but dissolving, and
the surrounding corneal edema had resolved (Figure 2B). There
was no fluorescein stain uptake. The pupil remained mydriatic
and no flare was detected. Small specks of pigment were noted
on the anterior lens capsule, but the lens was otherwise clear.
Fundic examination was normal. Atropine was discontinued and
0.1mL ofloxacin 0.3% o.s. and ¼ inch strip terbinafine 1% dermal
cream q8h were continued for 1 additional week. The alpaca was
rechecked by the rDVM at 6 weeks after surgery and reported to
be comfortable and visual with no signs of decline after stopping
the medications 1 week prior. Telephone and photo updates with
the owner and rDVM 12months post-surgery confirmed that the
alpaca remains visual and comfortable with minimal scarring. A
complete treatment timeline is provided (Figure 3).
DISCUSSION
This study documents the clinical features and therapeutic
interventions in an alpaca with a full thickness corneal
fungal abscess, adding to the paucity of information about
keratomycosis in the species. These two fungal species
(Scopulariopsis brevicaulis and Fusarium verticillioides) have not
previously been reported in the cornea of an alpaca and were
successfully managed with a combination of surgery (PK) and
antifungal therapy (caspofungin 0.5% and terbinafine 1%).
The first fungus Scopulariopsis brevicaulis diagnosed in
this report was obtained from a superficial swab over the
ulcerated cornea. Scopulariopsis is considered an uncommon
pathogen both within normal commensal flora and clinical
infectious keratitis patients. In humans, Scopulariopsis brevicaulis
is considered a rare but emerging pathogen that is increasingly
recognized as a causative agent for superficial and deep mycoses,
most commonly in onychomycosis (toenail infections); however,
cases of fungal keratitis and endophthalmitis have been reported
(7). Scopulariopsis was isolated, in conjunction with several
bacteria and other fungi, in a single llama with conjunctivitis
and non-ulcerated superficial keratitis; however, the significance
of that fungus was unknown (1). Scopulariopsis was also isolated
from the conjunctival or corneal samples in a few healthy horses
and horses with ulcerative keratitis (11–14). Moore et al. (11)
did not report sensitivity panels for fungi isolated in horses
while Betbeze et al. (14) reported that all fungal isolates tested
in their study were sensitive to silver sulfadiazine and some were
sensitive to natamycin; however, specific minimum inhibitory
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FIGURE 3 | Timeline of the alpaca’s clinical course and treatments. Black stars indicate specific treatments and results. Day 4: Corneal cross-linking performed and
subconjunctival injection of 0.5ml voriconazole 1%. Day 9: Culture growth of Scopulariopsis brevicaulis. Day 10: Surgical lamellar keratectomy, penetrating
keratoplasty, and island conjunctival graft. Day 11: Parenteral ceftiofur crystalline-free acid once. Day 20: Culture growth of Fusarium verticillioides. Day 37: Recheck at
ISU–considered healed. Day 51: Recheck with rDVM–no relapse off medication. Day 375: Telephone and photo updates with owners and rDVM–small scar, no
concerns. Details about the products and dosages can be found in the main text. ¶ = pantoprazole (yellow bar).
concentration (MIC) values for the single Scopulariopsis isolate
were not stated (11, 14).
Scopulariopsis sp. have demonstrated resistance to numerous
antifungals both in vitro and in vivo (7–9). One in vitro study
reported that terbinafine and caspofungin had the best activity
of the 11 drugs tested, with low MIC and minimum effective
concentrations (MEC) (15). Another in vitro study found that
triple combination therapy with posaconazole, caspofungin, and
terbinafine showed a significant decrease in MIC compared to
any agent alone (8). Debridement of infected tissue, in addition
to a combination of chemotherapies, has been recommended
(7). Successful treatment of corneal Scopulariopsis brevicaulis
with amphotericin B or natamycin as monotherapies has been
reported, although the appropriate therapy is undetermined, as
treatment failure has also been reported (8, 9).
The second culture performed from the deep stroma debrided
at the time of surgery isolated Fusarium verticillioides. Fusarium
is a common pathogen reported in keratomycoses in horses
and humans, and two of the 11 previously reported alpacas
with keratomycosis were positive for Fusarium solani (3, 6, 10).
The therapeutic response of Fusarium is variable among its
different species (16). Fusarium species do not have a consistent
MIC and MEC distribution, leading to difficulty in predicting
antifungal susceptibility of a single strain (17). Susceptibility
patterns in veterinary clinical isolates of Fusarium are generally
most responsive to polyenes, including amphotericin B and
natamycin and are often considered to be multidrug resistant,
although only a select set of antifungals were tested in these
studies (14, 18, 19). Of note, terbinafine was reportedly the most
active drug against 24 clinical isolates of Fusarium verticillioides
in one study, but terbinafine efficacy was not assessed in the
other studies (14, 18–20). Echinocandins (e.g., caspofungin) have
variable activity against Fusarium species (17, 21).
Medical treatment of keratomycosis should consider
susceptibility of the organism to the drug, corneal penetration
of the drug, corneal toxicity, or other adverse reactions, and
medication cost. Previously reported antifungal medications
in camelids with fungal keratitis include silver sulfadiazine,
miconazole, itraconazole, and natamycin (1, 3). In this case
report, the alpaca was treated with caspofungin and terbinafine,
after failure to respond to topical voriconazole, given the
reported synergy between these two antifungal medications,
especially for Scopulariopsis brevicaulis, as well as financial
considerations (15).
Terbinafine has variable but often good efficacy against
Scopulariopsis sp., good efficacy against Fusarium sp., is non-
irritating to the cornea and very low cost to the client (7, 8,
15, 20, 22–24). Terbinafine is an allylamine antifungal agent and
works by inhibiting ergosterol synthesis through inhibition of
squalene epoxidate resulting in toxic intracellular accumulation
of the precursor squalene (10, 22). Terbinafine is available over
the counter as a dermatologic ointment for treatment of fungal
skin disease. The dermatologic ointment is not recommended
for use in the eye by the manufacturer but was successfully
used without any signs of ocular irritation for the treatment of
equine keratomycoses and for a rabbit with Aspergillus fumigatus
keratomycosis, as well as in the case presented here (23).
Terbinafine has variable corneal penetration. In rabbits, 0.2%
terbinafine suspended in corn oil achieved measurable levels in
both the cornea and aqueous humor at a concentration adequate
for inhibition of most fungal species (22). However, there was
no detectable level of drug in the cornea or aqueous humor after
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administration of 0.2% terbinafine suspended in castor oil in the
horse (24). The variable findings in these reports may highlight
a difference in vehicle or species. To the authors’ knowledge, no
studies have evaluated the corneal penetration of terbinafine 1%
dermatologic ointment.
Caspofungin is an echinocandin antifungal agent and works
by inhibiting the synthesis of 1,3-d-glucan, leading to cell lysis
from increased cell wall permeability (21). Caspofungin is most
often reconstituted to 0.5% for eye drops with 0.9% sodium
chloride for appropriate osmolality, with stability for 4 weeks
under refrigerated conditions (21). Caspofungin penetrates
through the cornea with a compromised epithelium (but not
intact), resulting in aqueous humor drug levels above MICs for
most fungi (21). Caspofungin has variable but sometimes good
efficacy against Scopulariopsis sp., variable but sometimes good
efficacy against Fusarium sp., shows no signs of corneal toxicity
or irritation, and is intermediate cost to the client (7, 8, 15, 21, 25).
No adverse reactions to any topical medications were noted in
this case.
In this case report, moderate bullous keratopathy and
keratomalacia were noted prior to surgery and improved with
CXL treatment. NewWorld camelids have a tendency to develop
marked corneal edema following injury, uveitis, and surgery,
and is thought to be due to their inherent corneal endothelial
pleomorphism and polymegathism (26). CXL is described as
treatment for bullous keratopathy in dogs and humans, as well as
for keratomalacia in various species, by stopping stromal melting
within 24 h and improving corneal edema in the short-term
(27, 28). The alpaca in this case report responded favorably to
CXL as the progressive keratomalacia and stromal bullae halted
after treatment. Since these corneal changes were associated with
the infectious keratitis, there was no recurrent corneal edema
after healing from the infection. Unfortunately, the evidence
to support use of CXL to help eradicate fungal organisms is
lacking and inconclusive; (6) which is in agreement with this
case’s findings.
This alpaca was treated with topical NPB and ofloxacin
ophthalmic preparations prior to presentation and diagnosis of
keratomycosis. The use of topical antibiotics has been suspected
to predispose horses to corneal fungal infections (29). However,
a decrease in positive fungal cultures were found after 2 weeks
of NPB in normal horses (13). Additionally, in both normal
dogs and horses, 1 week of NPB treatment did not significantly
disrupt major bacterial taxa as measured by next generation
sequencing (30, 31). Conversely, in dogs, topical ofloxacin for 3
weeks after cataract surgery has been shown to lead to a decrease
in positive bacterial cultures during treatment, an increase in
positive bacterial cultures 3 weeks after stopping treatment, and
an alteration in bacterial sensitivity (32). The authors cannot
conclude if the topical antibiotic therapy predisposed this patient
to keratomycosis, as topical antibiotics are standard of care
upon diagnosis of a corneal ulcer and corneal samples were not
obtained prior to starting these medications.
The use of a PK has not yet been described in a camelid to the
authors’ knowledge. However, it is commonly reported in horses
to treat full thickness corneal abscesses with a 78% success rate
(10). Penetrating keratoplasties are also described for treatment
of human keratomycosis, including a case report of Scopulariopsis
fungal keratitis in a man that failed treatment with amphotericin
B and itraconazole, highlighting the importance of debulking the
fungal infection when medical therapy fails (33). The authors
feel that the large lamellar keratectomy and smaller PK to excise
the fungal abscess were paramount in the treatment success.
However, it is unknown if this case would have experienced a
successful outcome with change in medical therapy alone.
Alpacas are raised for meat in multiple parts of the world (34).
However, camelids are not officially considered a food animal
in the US and are currently categorized as a minor species (35).
Recently, there has been an increase in alpaca meat production in
the Northeastern United States, due to interest in the native use
of the species as a dual purpose animal, despite lack of regulatory
oversight (36). While the alpaca in this case was a companion
animal, several aspects of treatment would be impermissible in
food animals (e.g., extra-label use of ofloxacin) or would have
unknown and presumptive long withdraw recommendations
(e.g., antifungals). Thus, the authors recommended the animal
to never enter the food chain.
The main limitations of this study were finite in-person
follow-up due to geographic restrictions and the lack of
susceptibility testing on the specific strains of fungi cultured.
Susceptibility testing would have strengthened the speculation
that terbinafine and caspofungin were effective in clearing any
remaining fungal infection but was not performed due to
financial limitations and the prolonged time it takes to obtain
fungal susceptibility results.
CONCLUSION
The alpaca presented in this report demonstrates that deep
keratomycosis can be caused by Scopulariopsis brevicaulis and
Fusarium verticillioides, two previously unreported fungi to
cause keratomycosis in camelids. This report also demonstrates
successful management with a combination of surgery and
topical ophthalmic treatment with caspofungin 0.5% solution
and terbinafine 1% dermatologic cream, after failure to respond
to voriconazole 1% solution. Combination therapy appears more
effective than monotherapy with some fungal organisms, and
synergy between antifungal agents is thought to play a role in
treatment success. Surgical debulking of the fungal infection is
especially helpful in cases that fail initial medical therapy.
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